Insud (Innovation, Sustainability and Development) is a business ecosystem with global reach that develops innovative solutions with a sustainability commitment to help improve fundamental aspects of human life: health, food and nutrition, energy and culture. In the pharmaceutical/biotechnology field, it operates throughout the value chain, providing its specialized knowledge in scientific research, development, manufacturing, sales and marketing of a wide range of products for human health. Insud Argentina stands out by developing monoclonal antibodies, vaccines and polyclonal immunotherapeutic sera. Nowadays we are developing alternative proteins, together with biotech startups. | Insud is a highly diversified group with global presence that operates across the entire pharmaceutical/biotech value chain, delivering specialized expertise in scientific research, development, manufacturing, sales and marketing of a wide range of compounds for human care. Insud Argentina stands out by developing monoclonal antibodies, vaccines and immunotherapeutic polyclonal sera.
IBEX Therapeutics SA
Ibex Therapeutics is Swiss biotech company developing a patented oral topical therapy to cure and prevent oral mucositis and oral candidiasis, debilitating conditions which very often occur as adverse effect of cancer chemo- and radiotherapy and affects the care journey and the quality of life of cancer patients. A de-risked and short path to registration and commercialization by 2028, as validated by the German health authority BfArM: the lead product (containing 2 water-based plant extracts) is produced in GMP conditions and has confirmed its efficacy and safety in a pilot study in cancer patients. Ibex Tx is raising CHF 3 million, of which 1.0+ million has already received soft commitments, with the largest part of the proceeds to fund a final pivotal clinical study, and some portfolio extensions (including a probiotic to synergize with the oral topical therapy, and a spray presentation to augment portability and convenience of use by ambulatory patients). Strong market fundamentals: sustained medical need (increasing incidence of cancer and use of mucositis-inducing therapies), and absence of reference treatment. Further, Ibex Tx will register the product in several geographies (EU, USA, Asia, BRICS), and sign licensing agreements to ensure efficient commercialization outside of Switzerland.
Hong Kong Science and Technology Parks Corporation (HKSTP)
Hong Kong Science & Technology Parks Corporation (HKSTP) is the largest innovation and technology hub in Hong Kong. It fosters a vibrant ecosystem for startups, enterprises, and researchers, offering incubation, acceleration, and investment opportunities. HKSTP operates Science Park, InnoCentre, and InnoParks across Hong Kong, driving advancements in life sciences, AI, fintech, and more. With strong global partnerships, state-of-the-art facilities, and talent development programs, HKSTP accelerates innovation and commercialization, contributing to Hong Kong’s position as a regional I&T leader.
Fundación INCIDE
The Innovation and Science Foundation for Business Development (INCIDE) is a non-profit organization, founded in 2013 by a group of mexican pharmaceutical companies, committed to technological development and innovation. INCIDE was created with the purpose of promoting scientific and technological development, as well as innovation, in biotech companies to generate value and competitive advantages and to collaborate in the economic and social development of companies and the country. The founding entrepreneurs have been shareholders of companies with more than 60 years in the pharmaceutical market, achieving their success on innovation processes that have projected them to generate patents and successfully venture into international markets. Our philosophy led us to collaborate with Universities and Public Research centers in order to foster science, technology and innovation in the pharma and health sectors. We implement 3 main open innovation strategies for Mexican pharmaceutical companies: 1) we run a program of innovation challenges where pharma companies identify a problem that need to be solved and we launch and open call to identify feasible solutions. The winners are funded to implement the selected project; 2) we launch an open call to incubate startups with pharma and health developments in early stage (since TRL 3) and prepare them to raise capital with Venture Capital Funds; 3) We are contributing to conform a Multi Corporate Venture Capital with investment thesis in health for startups in early stages (seed, pre Serie A and A Series). Finally, we also help Mexican pharma companies to identify in licensing opportunities for Mexican and Latinamerican markets, with a focus in small mollecules, vaccines, monoclonal antibodies and drug delivery systems. | The Fundación Innovación y Ciencia para el Desarrollo Empresarial (INCIDE) is a non-profit organization established in 2013, the result of a joint commitment by a group of Mexican companies with over six decades of experience, primarily in the pharmaceutical sector. These companies have built their growth and longevity on sustained processes of innovation, technological development, and patent generation, enabling them to compete successfully in international markets. The foundation fosters effective collaboration among companies, universities, and research centers, facilitating the creation of new technology-based enterprises and increasing private investment in science, technology, and innovation. Are you an academic / research institution looking for connection with mexican pharmaceutical companies? Let’s talk. INCIDE operates a Technology Observatory, a specialized tool for generating technology intelligence studies that help identify commercial opportunities, anticipate emerging technological trends, and support strategic decision-making in innovation. Are you interested in a Report that includes patents, clinical trials, resaerch projects funded, academic literature, market info, etc? Let’s talk. Additionally, INCIDE leads various technology scaling programs, including Innovation’s Challenge, an initiative carried out in collaboration with local government stakeholders to enhance public-private partnerships. Are you interested in solving the problems that mexican pharma companies have? Let’s talk about. The foundation also launches calls for the incubation of health-related technological products, through which investment portfolios are built for licensing innovations and accelerating their market entry. Are you an startup in early stage looking for tech transfer agreements with mexican pharma companies? Let’s talk. Its strategic objectives include identifying opportunities, managing portfolios of innovation and technological development projects, and promoting the active participation of both large enterprises and SMEs with innovation capacities. Furthermore, INCIDE seeks to position itself as an ethical and transparent entity that delivers concrete and measurable results for its members and for society at large.
Destination Medical Center, EDA
Destination Medical Center (DMC) is a unique 20-year economic development initiative. The $5.6 billion plan is the largest in Minnesota’s history. With the expansion of Mayo Clinic and DMC growth, Rochester is a global destination for health and wellness and so much more. Rochester, Minnesota is its own special place. It spawned the world-renowned Mayo Clinic, home to those leading the way in life science discoveries and health care innovations. It’s the place people go to get better. Where developers are building an epicenter fueled by economic boom and dramatic growth. Where entrepreneurs come to find their place and discover the next big thing. The Destination Medical Center (DMC) initiative puts you in the middle of it all. | The DMC Initiative serves as a public-private partnership, combining private development by Mayo Clinic and other developers, as well as public funding from the City of Rochester, Olmsted County, and the State of Minnesota to facilitate and support public infrastructure. DMC promotes the City of Rochester, and more broadly, the County, and the State as a world destination medical center, to assist the patients, caregivers, residents, employees, and visitors in fully experiencing Rochester as a premier destination medical center, while providing extended economic development and opportunities for the City, the region, and the State.
Department for Business and Trade
The UK’s Department for Business and Trade supports international investment into the UK and UK businesses to grow and export. Whether you’re interested in clinical research for innovative products, working with the UK’s world-leading universities, SMEs and spin outs, leveraging our globally-unique datasets or manufacturing complex products at pace and scale, the UK has a strong offer spanning Northern Ireland, Scotland and Wales and would like to work with you. We are joined by 16 inspired, innovative and international UK co-exhibitors eager to connect with you. | Connect with the UK Invest in the UK: Access free, confidential advice and support on your inward investment journey. Buy from the UK: The UK’s thriving life sciences sector has a lot to offer the world, from innovative products to expert services. Export from the UK: We Provide insights, training, events, finance and expert support so exporters can realise the full benefits of internationalising. Innovate with the UK: Connect into our networks to partner with UK academia, research institutes, centres of excellent and spinouts. Talk to us today and continue connecting with the UK in your home country via our teams based in over 100 international markets. | This UK government department specialises in helping UK businesses and bringing investment into the UK.
Chitozan Health LLC
Chitozan Health is an antimicrobial company seeking to commercialize antimicrobial materials that minimize the tendency for resistance to develop in bacteria and fungal threats. We are currently focused on launch of an advanced burn and wound gel in collaboration with the Medical University of South Carolina and the Chief of Burn Surgery Dr. Steven Kahn. Other products in stages of development are an antimicrobial flame-resistant textile finish, an anti-fungal barrier packaging coating, topical skin disease treatments, and an inhaled therapeutic for treatment of chronic lung infections caused by pseudomonas aeruginosa and mycobacteria.
Business Oregon
Life Science/Bioscience is one of Oregon’s leading Target Industries, and has become an emerging, competitive segment of the state’s economy. Oregon is also one of only six states that has been chosen to receive US Federal funding to develop a Microfluidics Hub called CorMic in Corvallis, Oregon. This represents the possibility of Billions of dollars in future Life Science Development for Oregon. Due to a recent expansion and influx of firms, like Genentech (a Roche subsidiary) and Twist Bioscience, Oregon’s bio community is growing faster and gaining more market share vs. many other U.S. states. With nearly 1,500 establishments, Oregon’s Bio market produced $15.7 billion (2022) in economic output, and nearly $1 billion in pharmaceuticals, medicine, and medical equipment. As one of the fastest growing parts of Oregon’s innovation economy, bioscience is generating exciting new research, life-changing products, and attracting increased amounts of venture capital, and foreign direct investment. | Business Oregon is the State of Oregon’s economic development agency. Bioscience is one of Oregon’s leading Target Industries and has become an emerging, competitive segment of Oregon’s economy. Major Life Science/Bioscience firms like Genentech (a Roche Subsidiary), Lonza, ThermoFisher Scientific, and Twist bioscience all have significant facilities in Oregon, and our bio community is growing faster and gaining more market share vs. many other U.S. states. With nearly 2,000 companies and 75,000 employees, Oregon’s Bioscience market produced $21.2 billion (2023) in total economic output, and $5.6 billion in pharmaceutical, medicine, and medical equipment exports. As one of the fastest-growing parts of Oregon’s innovation economy, bioscience is generating exciting new research, and life-changing products, and attracting increased amounts of venture capital, and foreign direct investment. Our core functions include business retention, expansion, and recruitment; export promotion and international trade; industry research and development and entrepreneurship; small business assistance; rural community development and infrastructure financing; and support for arts and cultural organizations.
BDO Life Sciences & BioProcess Technology Group
BDO’s BioProcess Technology Group is the recognized worldwide leader in biopharmaceutical CMC consulting, providing a full range of technical, regulatory, operational and strategic assistance to pharmaceutical and biotechnology companies in the development and commercialization of biopharmaceutical products. The company works with clients globally to find and apply solutions to the challenges of biopharmaceutical product development from clone to commercial®. BPTG helps develop manufacturing processes and strategies that enhance the overall value of client companies and accelerate the advancement of new products from clone to clinic®. BPTG also helps investors, service providers, and companies make informed decisions by providing technical due diligence services and business evaluations of new products as well as technologies for product discovery, development, or commercialization. | Accelerating biopharmaceutical process development. BDO’s BioProcess Technology Group (BPTG) is a world leader in providing strategic, technical, regulatory and business consulting services to the biopharmaceutical industry. We understand firsthand the challenges of developing and commercializing new products and technologies. BPTG provides full-service, flexible and responsive biotech consulting services to help clients through complex technical and regulatory issues, allowing them to achieve key business milestones. The breadth of our experience is extensive, ranging across business strategy, due diligence, chemistry, manufacturing and controls (CMC) advisory, supply chain planning, make vs buy, Cost of Goods Manufactured (COGM) modeling, expert witness testimony and more. We can help you manage all elements of drug development either across the product life cycle or for targeted, short-term consultations on specific technical, quality, regulatory or operational issues. Our technology consultants have an average of 30 years of industry experience from big pharma to startups. We continually demonstrate our thought leadership across various disciplines and provide actionable insight, targeted analyses and practical strategies to help address the technical, quality and regulatory challenges of product development and commercialization. By applying our deep technical understanding and broad experience in biopharmaceuticals and bioprocess technologies, bioprocess technologies can play a key role in facilitating — and accelerating — your success.